Undiagnosed diabetes is the implant risk the overseas workup skips

Most people with diabetes can have dental implants, and the implants usually work. That is the part the alarmist version of this story gets wrong, so let me concede it up front. When blood sugar is well controlled, the published evidence supports implant survival approaching that of people without diabetes [1][4]. Diabetes is not a contraindication to implants. It is a variable to be measured and managed.

Here is the pivot. The thing that makes diabetes dangerous for an implant is not the diagnosis. It is the absence of one. The patient who knows they have diabetes and whose blood sugar is well controlled is a manageable case. The patient who has diabetes and does not know it, whose blood sugar has been quietly high for years, is the one walking into a sinus floor or a fresh extraction socket carrying a healing impairment that nobody has measured. The screen that catches that patient is a simple blood test called HbA1c. It is routine before implant surgery at home. It is routinely missing abroad. This is the first piece in our What the Intake Form Skips series, and it is the cleanest example of the pattern: a single cheap test that changes the plan, left off the form because running it does not help close the sale.

What HbA1c actually measures, and why a single number carries months

HbA1c is glycated hemoglobin: hemoglobin in your red blood cells that has had glucose chemically bonded to it. The more glucose circulating in the blood over time, the more of your hemoglobin ends up glycated. Because red blood cells live for roughly three to four months, the proportion of glycated hemoglobin reflects your average blood glucose over the previous two to three months rather than the single morning you happened to give the sample [3].

That is the property that makes it valuable. A fasting glucose tells you about one moment. An HbA1c tells you about a season. You cannot fast, panic, or skip breakfast your way to a reassuring HbA1c, which is exactly why it is used both to diagnose diabetes and to track control. The World Health Organization recommends an HbA1c of 6.5 percent, equivalent to 48 mmol/mol, as a diagnostic threshold for diabetes when the test is run to a properly standardised method [2]. Values below that, in the 5.7 to 6.4 percent band, are commonly read as indicating elevated future risk rather than established disease [3].

None of those are surgical decision rules. They are diagnostic thresholds. But for a planning surgeon they do something powerful: they convert a hidden, multi-month metabolic state into one number on a page. And once that number exists, the surgical conversation can actually happen.

The scale of the hidden population

This would be a small problem if undiagnosed diabetes were rare. It is not. The World Health Organization estimates that hundreds of millions of adults live with diabetes worldwide, and a substantial share of them are undiagnosed, meaning the disease is present and doing damage while the person has no idea [1]. Type 2 diabetes in particular can develop over years with few obvious symptoms. Plenty of people first learn they have it from an incidental blood test ordered for an unrelated reason.

An implant workup is exactly the kind of incidental opportunity that, at home, routinely catches these cases. The patient came in for teeth. They left with a referral to their GP because the pre-operative bloods flagged a high HbA1c. That handoff is invisible and unglamorous and it happens constantly, and it depends entirely on someone having ordered the test. Remove the test from the pathway and you remove the catch. The disease is still there. The implant goes in anyway. Nobody finds out until the implant fails to integrate or the peri-implant tissue breaks down, by which point the patient is on another continent.

The mechanism: how high blood sugar sabotages osseointegration

Osseointegration is the biological process that makes an implant work: a direct structural and functional connection forms between living bone and the titanium surface, with no fibrous tissue in between [4]. It is not a mechanical fact created in the operatory. It is a healing process that unfolds over weeks to months after the implant is placed, as bone cells lay down new mineralised matrix directly against the implant surface. If that healing is impaired, the implant never locks in, or it loosens later under load.

Chronic hyperglycemia impairs that healing through several converging routes, and the evidence on diabetes and implants points consistently in this direction [1]. Here is the chain in plain terms.

  Chronic high blood glucose
            |
            v
  Advanced glycation end-products (AGEs) accumulate in tissue
            |
   +--------+-----------------+------------------+
   v                          v                  v
 Impaired collagen      Microvascular        Altered immune /
 cross-linking,         damage: less          inflammatory
 stiffer matrix         blood flow to         response, poorer
                        the healing site      infection control
   |                          |                  |
   +-----------+--------------+---------+--------+
               v                        v
      Reduced new bone formation   Higher infection and
      and remodelling at the       peri-implant disease
      implant surface              risk
               |                        |
               +-----------+------------+
                           v
              Impaired osseointegration:
              slower, weaker, or failed
              bone-to-implant lock

Concede the limits of this picture honestly. The magnitude of the effect is debated, the studies vary in quality, and well-controlled patients often do fine [1]. The point is not that every diabetic implant fails. The point is that the mechanism is real, it scales with how high and how prolonged the blood sugar has been, and the single best proxy for that exposure is the HbA1c the overseas form did not ask for.

Why “well controlled” is the actual decision variable

If you read the implant-and-diabetes literature as a whole, the recurring finding is that the diabetes label matters far less than the degree of control [1]. People with well-controlled diabetes have implant outcomes that approach those of people without diabetes. People with poor control carry meaningfully higher risk of impaired integration, infection, and peri-implant breakdown.

That reframes the entire question. The right pre-operative question is not “do you have diabetes,” which is a yes or no a nervous patient may answer wrongly or incompletely. The right question is “what is your HbA1c,” which is a number that does not lie and does not depend on the patient knowing their own status. A patient with undiagnosed diabetes will truthfully answer “no” to the first question and fail the second. Only the second question protects them.

At home, the planning dentist is embedded in a system that makes this easy: a GP record, a shared pathway to order bloods, a culture of pre-operative screening, and a financial structure that does not punish the dentist for surfacing a delay. The overseas one-trip model strips out every one of those supports. The same gap that lets a clinic skip the HbA1c is the gap behind the broader dental tourism trust problem: the incentives of a single transaction are not aligned with a multi-month healing process the clinic will never have to witness.

The package-deal incentive, applied to a blood test

It is worth being specific about why this test in particular goes missing, because the answer is structural rather than careless. A pre-operative HbA1c can do three inconvenient things to a booked implant trip. It can add a day or a lab fee. It can return a result that mandates a delay while control is improved. And it can, occasionally, cancel the surgery outright by revealing a patient who should be optimised first.

Every one of those outcomes is good medicine and bad for a fixed-itinerary booking. The same commercial logic that drives package-deal overtreatment drives package-deal underscreening: anything that threatens the planned procedure on the planned dates is friction to be removed, and a blood test that might say “not yet” is friction. The home dentist has no equivalent pressure, because the home dentist is not selling a holiday with a deadline. This is also why the decision of when to go overseas for dental treatment should hinge partly on whether the systemic workup travels with you or gets left at the airport.

What a patient should verify

This is a decision framework, not treatment advice. No number here tells you whether to proceed; that is for a clinician who has your full history. But three concrete, checkable items separate a real systemic workup from a procedural intake.

1. Confirm an HbA1c was ordered and that you have seen the result. Ask, before you travel, whether pre-operative bloods including HbA1c are part of the plan, where they will be run, and whether the result will be reviewed and explained to you before any implant is placed. A workup you cannot see is a workup you cannot trust. If the answer is that no bloods are taken, that is itself the finding.

2. Have your home GP run the screen before you leave. The cleanest fix for the void is to not depend on the clinic at all. Ask your home GP for a pre-operative HbA1c, and ideally a brief written note of your control status, weeks before departure. If it is high, you have learned something that protects you whether or not you ever board the plane. If it is reassuring, you carry a document the overseas team can act on.

3. Ask how a borderline or high result would change the plan. A clinic that screens properly can tell you, in advance, what it would do if your HbA1c came back elevated: delay, refer for optimisation, or proceed with documented informed consent about the raised risk. A clinic that cannot answer the question has told you the screen is decorative. The right answer involves the word “delay” being on the table at all.

The one question that changes the plan

Strip everything down and one question does the work the entire intake form is supposed to do: what is your HbA1c, and who has looked at it. That question converts an invisible, multi-year metabolic exposure into a number on the page, and it catches the one patient who most needs catching, the one who would honestly tick “no diabetes” because nobody has ever told them otherwise.

The home pathway asks that question almost reflexively, not because home dentists are wiser but because they are embedded in a system that rewards finding problems before surgery rather than after. The overseas one-trip pathway often does not ask it, not because anyone is reckless but because the incentives point the other way and the patient will be gone before the answer mattered. The same blind spot recurs across this series, from the single unasked question that stands between a patient and MRONJ to the drug-interaction void created by the missing shared record and the blood-pressure screen that gates a long sedation session. In every case the protection is cheap, the omission is structural, and the cost lands on the one patient who never knew the screen existed. For how we weigh and source these claims, see our methodology.